The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Global specialty pipeline accelerates growth
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
Subscribe To Our Newsletter & Stay Updated
